原发性干燥综合征治疗的荟萃分析
该荟萃分析纳入32项随机对照试验、评估19种药物,发现仅少数试验显示眼干和口干有统计学显著改善,6个月时免疫调节治疗可改善非刺激唾液流率并降低红细胞沉降率,但因不良事件退出风险增加。
要点
- 32项RCT中仅2项眼干、4项口干显示统计学显著改善,无药物表现出一致获益。
- 6个月时免疫调节治疗较安慰剂改善非刺激唾液流率(P=0.003)并降低红细胞沉降率(P=0.007)。
- 严重不良事件无差异,但因不良事件退出风险增加(RR 2.33;P=0.03)。
核心结论
- 减少炎症可能改善唾液腺功能,但无单个免疫调节药物在口干症和眼干症中表现出一致获益。
研究设计与样本
- 检索Medline、Embase、Central、ClinicalTrials.gov和WHO ICTRP五个数据库,纳入治疗原发性干燥综合征的随机对照试验。
- 共纳入32项试验,评估19种不同药物,平均诊断病程较长(长达9.2年)。
主要发现
- 无研究发泪液分泌获益;非刺激唾液流率16项RCT中3项、刺激唾液流率14项RCT中2项显示改善。
- 6个月荟萃分析显示非刺激唾液流率较安慰剂改善(P=0.003),红细胞沉降率下降(P=0.007)。
- 严重不良事件无差异,但因不良事件退出增加(风险比2.33;P=0.03)。
临床怎么用
- 免疫调节治疗可能改善唾液腺功能,但需权衡因不良事件退出的风险增加。
- 需进一步识别能从治疗中获益的干燥综合征患者,并采用有效且对变化敏感的研究终点。
局限性
- 纳入试验的平均诊断病程较长(长达9.2年),可能影响治疗反应评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The current focus of treatment in primary Sjögren's syndrome (SS) is symptom management. Since SS is an autoimmune disease with multisystem involvement, systemic immunosuppression may have a role in improving signs and symptoms and preventing progression. We undertook this review to assess the efficacy and safety of immunomodulation on primary SS from randomized clinical trials (RCTs). METHODS: Five electronic databases (Medline, Embase, Central, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform) were searched to include RCTs for the treatment of SS. Primary outcome measures included ocular dryness, oral dryness, tear production, and salivary function. Serious adverse events (AEs) and withdrawals due to AEs were also assessed. RESULTS: The search yielded 32 trials evaluating 19 different medications. The average duration of diagnosis was long (up to 9.2 years). Twenty-two trials examined ocular and oral dryness, for which only 2 and 4 trials showed statistically significant improvements, respectively. No studies found a benefit for tear production; few studies found improvements for unstimulated salivary flow (3 of 16 RCTs) and stimulated salivary flow (2 of 14 RCTs). Meta-analysis at 6 months found improvements as compared to placebo for unstimulated salivary flow (P = 0.003) and a decrease in the erythrocyte sedimentation rate (P = 0.007). No differences were seen for serious AEs, but there were increased withdrawals from AEs (risk ratio 2.33; P = 0.03). CONCLUSION: Reducing inflammation potentially improves salivary gland function. No individual immunomodulatory drug demonstrated a consistent benefit in xerostomia and xerophthalmia. Further work is needed to identify SS patients with an ability to improve and with outcomes that are valid and sensitive to change within clinical trials. Tradeoffs in the future between benefit and safety may also be important, because more withdrawals occurred with active treatment.
引用
- Chu LL, Cui K, Pope JE, et al. Meta-Analysis of Treatment for Primary Sjögren's Syndrome. Arthritis Care Res (Hoboken). 2020. PMID: 31058469. doi:10.1002/acr.23917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。